Drugs / Melan-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01308294 | Jun 2010 → Apr 2014 | melanoma | Centre Hospitalier Universitaire Vaudois | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00559026 Comparator | Sep 2004 → Sep 2006 | melanoma | Italian National Institute of Health | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Melan-A | “syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide” NCT01308294 ↗ |
| Modality | Vaccine | “anti-tumor vaccination with Melan-A and gp100 analog peptides” NCT00559026 ↗ |